Trial Profile
A phase 2/3 randomized, open-label, controlled, parallel-arm study of Ampligen in patients with advanced or metastatic late-stage pancreatic cancer
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Rintatolimod (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors AIM ImmunoTech
- 19 Oct 2021 According to an AIM ImmunoTech media release, the company has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the USA Food and Drug Administration (FDA) for this study.
- 04 Oct 2021 According to an AIM ImmunoTech media release, Prof. Kelsey Klute is the study's principal investigator in the United States.
- 04 Oct 2021 According to an AIM ImmunoTech media release, the company has finalized the protocol for a planned Phase 2 study and the company expects to submit both an Investigational New Drug application (IND) and an application for Fast Track status with the U.S. Food and Drug Administration (FDA) no later than October 18, 2021.